Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x

(CHMP) CfMPfHU. Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non‐valvular atrial fibrillation. Draft. London: European Medicines Agency, 2013.

Mehran, 2011, Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium, Circulation, 123, 2736, 10.1161/CIRCULATIONAHA.110.009449

Lancaster, 1991, The impact of long‐term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Arch Intern Med, 151, 1944, 10.1001/archinte.1991.00400100032005

Gould, 1999, Low‐molecular‐weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost‐effectiveness analysis, Ann Intern Med, 130, 789, 10.7326/0003-4819-130-10-199905180-00002

Goldhaber, 2011, Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients, N Engl J Med, 365, 2167, 10.1056/NEJMoa1110899

Cohen, 2013, Rivaroxaban for thromboprophylaxis in acutely ill medical patients, N Engl J Med, 368, 513, 10.1056/NEJMoa1111096

Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561

Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638

Hori, 2012, Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J‐ROCKET AF study, Circ J, 76, 2104, 10.1253/circj.CJ-12-0454

Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039

Connolly, 2011, Apixaban in patients with atrial fibrillation, N Engl J Med, 364, 806, 10.1056/NEJMoa1007432

Ogawa, 2011, Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non‐valvular atrial fibrillation. ‐The ARISTOTLE‐J study, Circ J, 75, 1852, 10.1253/circj.CJ-10-1183

Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907

Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903

Buller, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572

Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598

Schulman, 2014, Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, 764, 10.1161/CIRCULATIONAHA.113.004450

Schulman, 2013, Extended use of dabigatran, warfarin, or placebo in venous thromboembolism, N Engl J Med, 368, 709, 10.1056/NEJMoa1113697

Agnelli, 2013, Apixaban for extended treatment of venous thromboembolism, N Engl J Med, 368, 699, 10.1056/NEJMoa1207541

Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507

Hokusai, 2013, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, 1406, 10.1056/NEJMoa1306638